Wyeth PFE
-
VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's MRK Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful …
-
IXJ iShares S&P Global Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's MRK Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful …
-
New Morningstar Analyst Report - ViroPharma, Inc.
… question after the drug failed to reduce the rate of CMV disease for transplant patients in a Phase III trial.ViroPharma and Wyeth (now a part of Pfizer) broke off their partnership for the development of a hepatitis C drug after a Phase II trial revealed …
-
PPH Market Vectors Pharmaceutical ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful one …
-
XPH SPDR S&P Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful one …
-
PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-Phen, Merck's MRK Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful …
-
IHE iShares Dow Jones US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful one …
-
Have Investors Moved Past Europe?
On Wednesday Wyeth WYE announced second-quarter results, reporting sales and earnings increases ..... 48%, and 27%, respectively. While these gains were impressive, Wyeth 's total revenue growth was in line with our expectations, as sales …
-
Top 10 Dividend-Yielding Stocks of Our Ultimate Stock-Pickers
… several years, especially as the company's 2009 acquisition of Wyeth helps insulate it against any one particular patent loss. Several ..... Pfizer is significantly cutting its cost base as a result of the Wyeth acquisition, less marketing support for drugs losing patent …
-
Pfizer Looks Set To Dominate With Takeovers
… Viagra, and Celebrex. In my opinion, the recent acquisition of Wyeth in 2009 secures Pfizer's leading place in the market and will ..... and reliable growth in the near future. The acquisition of Wyeth in 2009 positioned Pfizer to take a leading position in the …